Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Br J Dermatol. 2019 Jul;181(1):202-203. doi: 10.1111/bjd.17604. Epub 2019 Mar 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Clinical Trials as Topic
  • Dermatologic Agents / adverse effects*
  • Female
  • Humans
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / immunology
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / epidemiology*
  • Latent Tuberculosis / immunology
  • Male
  • Middle Aged
  • Prevalence
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Severity of Illness Index
  • Treatment Outcome
  • Tuberculin Test

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • IL17A protein, human
  • Interleukin-17
  • ixekizumab